Once valued at $9B, Theranos to close

Amy Baxter | | Health Exec | Precision Medicine
6638074343_dab655b246_b.jpg

Theranos, the Silicon Valley-based blood-testing startup that was once valued at $9 billion, is dissolving. The company has been clad in scandal after reports revealed Theranos’ trademark service­–to test blood with a single pinprick–wasn’t effective or accurate.

Its founder, Elizabeth Holmes, once heralded as the next Steve Jobs by Inc. Magazine, and Sunny Balwani, Theranos’s former president and COO, are facing criminal charges for defrauding investors out of hundreds of millions of dollars.

The Washington Post first reported the story on the company’s closure, which was detailed in a note to shareholders issued Monday by CEO and General Counsel David Taylor. Theranos will pay its creditors after turning over its assets and intellectual property to Fortress, a credit and investment firm.

The move will leave Theranos with $5 million to pay creditors. It owes more than $60 million.

Read the full story below:

Blood-testing company Theranos will dissolve, pay creditors

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.